This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Belke, D. D. Articles by Dillmann, W. H. Search for Related Content PubMed PubMed Citation Articles by Belke, D. D. Articles by Dillmann, W. H.

Adeno-Associated Virus-Mediated Expression of Thyroid Hormone Receptor Isoforms-1 and -ß1 Improves Contractile Function in Pressure Overload-Induced Cardiac Hypertrophy

Department of Medicine, University of California, San Diego, La Jolla, California 92093-0618

Address all correspondence and requests for reprints to: Wolfgang H. Dillmann, Department of Medicine, 5063 Basic Sciences Building, University of California, San Diego, La Jolla, California 92093-0618. E-mail: wdillmann{at}ucsd.edu.

Pressure overload-induced cardiac hypertrophy leads to decreased contractile performance, frequently progressing to heart failure. Cardiac hypertrophy and heart failure can be accompanied by the so-called sick thyroid syndrome, resulting in decreased serum T₃ levels along with decreased expression of thyroid hormone receptors (TR1 and TRß1) and sarco(endo)plasmic reticulum Ca-ATPase (SERCA). Because the binding of T₃ occupied receptors to the thyroid response elements in the SERCA promotor can increase gene expression, we wanted to determine whether increasing TR expression in the hypertrophied heart could also improve SERCA expression and cardiac function. Mice subjected to aortic constriction to generate pressure overload-induced hypertrophy were also subjected to gene therapy using adeno-associated virus (AAV) expressing either TR1 or TRß1, with LacZ expressing AAV serving as control. After 8 wk of aortic constriction, a similar degree of hypertrophy was observed in all three groups; however, mice treated with TR1 or TRß1 showed improved contractile function. Administration of a physiological dose of T₃ increased serum T₃ levels only into the lower range of normal. This T₃ dose, with or without AAV TR treatment, did not result in any significant increase in contractile performance. Calcium transients measured in isolated myocytes also exhibited an enhanced rate of decay associated with TR1 or TRß1 treatment. Western blot analysis showed increased SERCA expression in the TR1- or TRß1-treated groups relative to the LacZ-treated control group. These results demonstrate that increasing TR expression in the hypertrophied heart is associated with an improvement in contractile function and increased SERCA expression.

This article has been cited by other articles:

				A. Makino, J. Suarez, H. Wang, D. D. Belke, B. T. Scott, and W. H. Dillmann Thyroid Hormone Receptor-{beta} Is Associated with Coronary Angiogenesis during Pathological Cardiac Hypertrophy Endocrinology, April 1, 2009; 150(4): 2008 - 2015. [Abstract] [Full Text] [PDF]

				O. M. Hyyti, A. K. Olson, M. Ge, X.-H. Ning, N. E. Buroker, Y. Chung, T. Jue, and M. A. Portman Cardioselective dominant-negative thyroid hormone receptor ({Delta}337T) modulates myocardial metabolism and contractile efficiency Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E420 - E427. [Abstract] [Full Text] [PDF]

				I. Klein and S. Danzi Thyroid Disease and the Heart Circulation, October 9, 2007; 116(15): 1725 - 1735. [Abstract] [Full Text] [PDF]

				C. Pantos, A. Dritsas, I. Mourouzis, A. Dimopoulos, G. Karatasakis, G. Athanassopoulos, S. Mavrogeni, A. Manginas, and D. V Cokkinos Thyroid hormone is a critical determinant of myocardial performance in patients with heart failure: potential therapeutic implications Eur. J. Endocrinol., October 1, 2007; 157(4): 515 - 520. [Abstract] [Full Text] [PDF]